Spots Global Cancer Trial Database for vandetanib
Every month we try and update this database with for vandetanib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer | NCT04211337 | Medullary Thyro... | Selpercatinib Cabozantinib Vandetanib | 12 Years - | Eli Lilly and Company | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| Addition of Vandetanib to Standard Therapy Pegliposomal Doxorubicin (PLD) | NCT00862836 | Ovarian Cancer | Vandetanib | 18 Years - | Sanofi | |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | NCT01582191 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Everolimus Laboratory Biom... Pharmacological... Vandetanib | - | M.D. Anderson Cancer Center | |
| Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors | NCT02015065 | GIST | Vandetanib | 3 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer | NCT00720083 | Head and Neck C... | cisplatin vandetanib radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | NCT00537095 | Thyroid Neoplas... | Vandetanib Placebo | 18 Years - | Sanofi | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | NCT00508001 | Carcinoma, Hepa... | Vandetanib Vandetanib Best Supportive... | 20 Years - | Sanofi | |
| Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer | NCT01191892 | Bladder Cancer Transitional Ce... Ureter Cancer Urethral Cancer | carboplatin gemcitabine hyd... vandetanib Placebo | 18 Years - 120 Years | Cardiff University | |
| Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy | NCT00686036 | Prostate Cancer | vandetanib Placebo | 18 Years - | Sanofi | |
| ZD6474 in Treating Patients With Small Cell Lung Cancer | NCT00066313 | Lung Cancer | vandetanib adjuvant therap... | 16 Years - 120 Years | Sanofi | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer | NCT02530411 | Neoplasms | Fulvestrant Vandetanib | 18 Years - | Velindre NHS Trust | |
| Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | NCT01661179 | Unresectable Lo... | Vandetanib 300m... | 20 Years - | Sanofi | |
| Study of GemOx and Vandetanib in Advanced Solid Malignancy | NCT00660725 | Advanced Incura... | Vandetanib Gemcitabine Oxaliplatin | 18 Years - | University of Pittsburgh | |
| SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer | NCT02299999 | Metastatic Brea... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Bicalutamide Olaparib Anthracyclines Taxanes cyclophosphamid... DNA intercalato... Methotrexate vinca alkaloids Platinum based ... Bevacizumab Mitomycin C Eribulin MEDI4736 | 18 Years - | UNICANCER | |
| Dose Escalation Study of Vandetanib With Hypofractionated Stereotactic Radiotherapy in Recurrent Malignant Gliomas | NCT00822887 | Malignant Gliom... | Vandetanib Fractionated St... | 18 Years - | University of Colorado, Denver | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer | NCT00496665 | Metastatic Brea... | Vandetanib Cyclophosphamid... Methotrexate | 18 Years - | Dana-Farber Cancer Institute | |
| Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | NCT00508001 | Carcinoma, Hepa... | Vandetanib Vandetanib Best Supportive... | 20 Years - | Sanofi | |
| A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC). | NCT04760288 | Medullary Thyro... | Pralsetinib Cabozantinib Vandetanib | 12 Years - | Hoffmann-La Roche | |
| Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients | NCT00418886 | Non Small Cell ... Lung Cancer | Vandetanib Pemetrexed | 18 Years - | Sanofi | |
| Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma | NCT01661179 | Unresectable Lo... | Vandetanib 300m... | 20 Years - | Sanofi | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | NCT00500292 | Colorectal Cancer | Vandetanib FOLFOX regimen=... | 18 Years - | Sanofi | |
| Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | NCT00821080 | Glioblastoma | Sirolimus Vandetanib | 18 Years - | Massachusetts General Hospital | |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | NCT03630120 | Thyroid Cancer Thyroid Cancer,... Differentiated ... Papillary Thyro... Follicular Thyr... Poorly Differen... | Lenvatinib Sorafenib Cabozantinib Vandetanib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy | NCT00777179 | NSCLC | Vandetanib Placebo | 18 Years - | Sanofi | |
| Phase I Chinese PK | NCT00503711 | Advanced Solid,... | Vandetanib Vandetanib 300 ... | 18 Years - | Sanofi | |
| A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer | NCT00500292 | Colorectal Cancer | Vandetanib FOLFOX regimen=... | 18 Years - | Sanofi | |
| Study of GemOx and Vandetanib in Advanced Solid Malignancy | NCT00660725 | Advanced Incura... | Vandetanib Gemcitabine Oxaliplatin | 18 Years - | University of Pittsburgh | |
| Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma | NCT00681798 | Pancreatic Canc... | Vandetanib | 18 Years - | Sanofi | |
| ZD6474(Vandetanib) + Alimta Combo Study | NCT00506051 | Carcinoma Non-Small Cell ... Lung Cancer | ZD6474 (vandeta... pemetrexed ZD6474 (vandeta... | 18 Years - | Sanofi | |
| Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction | NCT00732745 | Adenocarcinoma ... Esophageal Canc... | docetaxel oxaliplatin vandetanib placebo | 18 Years - | Case Comprehensive Cancer Center | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| Efficacy and Safety of Vandetanib (ZD6474) in Patients With Metastatic Papillary or Follicular Thyroid Cancer | NCT00537095 | Thyroid Neoplas... | Vandetanib Placebo | 18 Years - | Sanofi | |
| ZD6474(Vandetanib) + Alimta Combo Study | NCT00506051 | Carcinoma Non-Small Cell ... Lung Cancer | ZD6474 (vandeta... pemetrexed ZD6474 (vandeta... | 18 Years - | Sanofi | |
| A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study | NCT02013089 | Gastrointestina... | Erlotinib or Ge... Everolimus Imatinib Sorafenib or Su... Vandetanib | 18 Years - 70 Years | Sun Yat-sen University | |
| Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | NCT00364351 | Non Small Cell ... | Vandetanib Erlotinib | 18 Years - | Sanofi | |
| Trial Assessing Zactima Against Placebo in Prostate Cancer Subjects Undergoing Intermittent Androgen Deprivation Hormonal Therapy | NCT00686036 | Prostate Cancer | vandetanib Placebo | 18 Years - | Sanofi | |
| A Trial of ZD6474, Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation Therapy Followed by Surgery | NCT01183559 | Cancer of the E... Adenocarcinoma ... Cancer of the S... | Vandetanib 5 Fluorouracil ... Carboplatin Paclitaxel External Beam R... | 18 Years - | Fox Chase Cancer Center | |
| Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | NCT00687297 | Lung Cancer Non Small Cell ... | vandetanib indu... Docetaxel Carboplatin Placebo Vandetanib main... | 18 Years - | PrECOG, LLC. | |
| Vandetanib in Advanced NSCLC With RET Rearrangement | NCT01823068 | Non Small Cell ... | Vandetanib | 18 Years - | Samsung Medical Center | |
| SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | NCT02117167 | Non-small Cell ... | AZD2014 AZD4547 AZD5363 AZD8931 Selumetinib Vandetanib Standard mainte... Pemetrexed Durvalumab savolitinib Olaparib | 18 Years - | UNICANCER | |
| Vandetanib to Treat Advanced Kidney Cancer | NCT01372813 | Advanced Clear ... | vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | NCT00745732 | Non-Small Cell ... | ZD6474 (ZACTIMA... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy | NCT02638428 | Relapsed Pediat... Refractory Pedi... Relapsed Pediat... Refractory Pedi... | CancerSCAN™ Ifosfamide Carboplatin Etoposide Fludarabine Cytarabine Pazopanib Sorafenib Axitinib Crizotinib Dasatinib Erlotinib Everolimus Imatinib Ruxolitinib Vandetanib Vemurafenib Trastuzumab | - 18 Years | Samsung Medical Center | |
| E3-Hormone Refractory Prostrate Cancer Taxotere Combination | NCT00498797 | Prostate Cancer Metastatic Hormone Refract... | Zactima (vandet... Docetaxel Prednisolone | 18 Years - | Sanofi | |
| ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer | NCT00312377 | Non-small Cell ... Lung Cancer | Docetaxel Vandetanib | 18 Years - | Sanofi | |
| Vandetanib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Diffuse Brainstem Glioma | NCT00472017 | Brain and Centr... | vandetanib | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ph I Dose Escalation Trial of Vandetanib in Combo w Etoposide for Malignant Gliomas | NCT00613223 | Gliosarcoma Glioblastoma | Vandetanib and ... | 18 Years - | Duke University | |
| Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | NCT01582191 | Advanced Malign... Metastatic Mali... Recurrent Malig... Refractory Mali... | Everolimus Laboratory Biom... Pharmacological... Vandetanib | - | M.D. Anderson Cancer Center | |
| Phase I Chinese PK | NCT00503711 | Advanced Solid,... | Vandetanib Vandetanib 300 ... | 18 Years - | Sanofi | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | NCT00757692 | Prostate Cancer | Vandetanib Bicalutamide | 18 Years - | British Columbia Cancer Agency | |
| Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer | NCT00753675 | Biliary Tract C... Gallbladder Can... Cancer Of The E... Ampullary Carci... | ZD6474, Vandeta... ZD6474, Vandeta... Gemcitabine Placebo matchin... | 18 Years - | Sanofi | |
| Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | NCT00821080 | Glioblastoma | Sirolimus Vandetanib | 18 Years - | Massachusetts General Hospital | |
| ZD6474 in Treating Patients With Small Cell Lung Cancer | NCT00066313 | Lung Cancer | vandetanib adjuvant therap... | 16 Years - 120 Years | Sanofi | |
| Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | NCT00757692 | Prostate Cancer | Vandetanib Bicalutamide | 18 Years - | British Columbia Cancer Agency | |
| Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | NCT00508001 | Carcinoma, Hepa... | Vandetanib Vandetanib Best Supportive... | 20 Years - | Sanofi | |
| Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients | NCT00418886 | Non Small Cell ... Lung Cancer | Vandetanib Pemetrexed | 18 Years - | Sanofi | |
| S0904: Docetaxel With or Without Vandetanib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | NCT00872989 | Fallopian Tube ... Ovarian Cancer Primary Periton... | docetaxel vandetanib | 18 Years - 120 Years | SWOG Cancer Research Network | |
| Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer | NCT00481845 | Breast Cancer | Vandetanib Anastrozole | 18 Years - | Stanford University | |
| Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma | NCT00613054 | Glioblastoma Gliosarcoma | Zactima, Gleeve... | 18 Years - | Duke University | |
| A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | NCT00923247 | Medullary Thyro... | Bortezomib Vandetanib | 18 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer | NCT00514046 | Medullary Thyro... Multiple Endocr... Multiple Endocr... | Vandetanib | 5 Years - 18 Years | National Institutes of Health Clinical Center (CC) | |
| Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions | NCT01414426 | Lip and Oral Ca... Oral Cavity Ver... Precancerous Co... | vandetanib placebo immunohistochem... laboratory biom... biopsy pharmacological... | 18 Years - | University of Chicago | |
| Chemotherapy and Radiation Therapy (RT) With or Without Vandetanib in Treating Patients With High-Risk Stage III or Stage IV Head and Neck Cancer | NCT00720083 | Head and Neck C... | cisplatin vandetanib radiation thera... | 18 Years - | Radiation Therapy Oncology Group | |
| BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC | NCT00410189 | Lung Cancer | ZD6474 | 18 Years - | M.D. Anderson Cancer Center | |
| Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer | NCT00753675 | Biliary Tract C... Gallbladder Can... Cancer Of The E... Ampullary Carci... | ZD6474, Vandeta... ZD6474, Vandeta... Gemcitabine Placebo matchin... | 18 Years - | Sanofi | |
| Vandetanib to Treat Advanced Kidney Cancer | NCT01372813 | Advanced Clear ... | vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study | NCT02013089 | Gastrointestina... | Erlotinib or Ge... Everolimus Imatinib Sorafenib or Su... Vandetanib | 18 Years - 70 Years | Sun Yat-sen University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
